<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/112FC30F-7343-4F4C-B4CA-04986C09EF61"><gtr:id>112FC30F-7343-4F4C-B4CA-04986C09EF61</gtr:id><gtr:firstName>Saul</gtr:firstName><gtr:surname>Tendler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/83A3C1BE-4339-486A-ADC5-F98EC72F542E"><gtr:id>83A3C1BE-4339-486A-ADC5-F98EC72F542E</gtr:id><gtr:firstName>Gerry</gtr:firstName><gtr:surname>Pattenden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200641"><gtr:id>EB27FEEF-0A71-49C9-A3D9-E6F24DB24EDE</gtr:id><gtr:title>University of Nottingham - Bridging the Physical/Life science divide</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200641</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>252856</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Promethean Particles</gtr:companyName><gtr:description>A spin-out company from the University of Nottingham that has developed a unique reactor technology to allow unprecedented product control and flexibility in inorganic nanoparticle dispersion manufacture.; http://www.prometheanparticles.co.uk/</gtr:description><gtr:id>B87B691C-8F60-41EC-80BC-3F2686F3F401</gtr:id><gtr:impact>Promethean Particles was spun-out from the University of Nottingham in February 2008 after receiving seed-corn investment from the Lachesis Fund (managed by SPARK Venture Management, formerly Questor) and Catapult. The technology at the centre of Promethean Particles, the reactor, was fully developed at the University of Nottingham, including the construction of a pilot scale facility prior to company formation and is protected by a patent application that has progressed to National / Regional phase. WINNERS of the UK NanoForum &amp;amp; Emerging Technologies 2009 for the Business Innovation Award in the category for Materials &amp;amp; Devices Promethean Particles won the LORD STAFFORD AWARD for Innovation Achieved September 2009</gtr:impact><gtr:outcomeId>F611B872CD8</gtr:outcomeId><gtr:url>http://www.prometheanparticles.co.uk</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>60C83ED8-05C0-4F7E-9888-436EFE8B96C8</gtr:id><gtr:title>Rewritable imaging on the surface of frozen ionic liquids.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bcb6587f5360a54923d265e1122eb"><gtr:id>259bcb6587f5360a54923d265e1122eb</gtr:id><gtr:otherNames>Rutten FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>34B0ED47BD5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0473F1B5-0ED0-4750-B0CC-FFCD1C79892D</gtr:id><gtr:title>Nucleation and growth of insulin fibrils in bulk solution and at hydrophobic polystyrene surfaces.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d30ab37c6bf19dcf501f096719a94dce"><gtr:id>d30ab37c6bf19dcf501f096719a94dce</gtr:id><gtr:otherNames>Smith MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>E9A9E170FEF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200641</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1A41A859-2076-46E6-B80F-CE4E1E8EDC1D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.5  Resources and infrastructure (underpinning)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>